Sign in
Taking people in United StatesNo phase

Optimal Ventilation for Cardiac Arrest

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Atlanta, Austin, Boston, Chapel Hill, Cincinnati, Columbus, Dallas, Denver, Indianapolis, Iowa City, Milwaukee, New Hyde Park, Orange, Palo Alto, Philadelphia, Richmond, Seattle, St Louis, and Wilmington, United StatesSee the 20 sites
Trial code
Status
Recruiting
People taking part
1,530 people, planned
Started
1 Oct 2025
Expected to end
31 Mar 2030
Type of study
Interventional, 14 groups
Treatments tested
  • OPTI-VENT Bundle
  • Transition
  • None - control
Record updated
21 October 2026

Who can take part

Age
37 weeks to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Invasive airway in place at the start of CPR or airway placed within the first 5 minutes
  • Received at least 1 minute of CPR

Who cannot take part

  • Lack of commitment to aggressive ICU therapies (e.g., CPR performed as part of end-of-life care
  • Brain death determination prior to the CPR event
  • Out-of-hospital cardiac arrest was the reason for initial admission to the hospital (known poor outcomes)
  • Supported by Veno-Arterial Extra Corporeal Membrane Oxygenation at the start of CPR

Where in United States

  • Children's Healthcare of AtlantaAtlanta, United StatesContact: Stephanie BrownTaking people
  • Dell Children's Medical CenterAustin, United StatesContact: Hunter DaigleTaking people
  • Boston Children's HospitalBoston, United StatesContact: Catherine RossTaking people
  • UNC Children's HospitalChapel Hill, United StatesContact: Afsaneh PirzadehTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Daniel LoebTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: John JenningsTaking people
  • Medical City Children's HospitalDallas, United StatesContact: Tia RaymondTaking people
  • UT Southwestern Medical CenterDallas, United StatesContact: Priscilla YuTaking people
  • Children's Hospital ColoradoDenver, United StatesContact: Lorel HuberTaking people
  • Riley Children's HealthIndianapolis, United StatesContact: Maria FrazierTaking people
  • Stead Family Children's HospitalIowa City, United StatesContact: Sarah HaskellTaking people
  • Children's WisconsinMilwaukee, United StatesContact: Andrea MaxwellTaking people
  • Cohen Children's Medical CenterNew Hyde Park, United StatesContact: Todd SwebergTaking people
  • CHOCOrange, United StatesContact: Jennifer HayesTaking people
  • Lucile Packard Children's Hospital - StanfordPalo Alto, United StatesContact: Azadeh FayaziTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Amanda O'HalloranTaking people
  • Children's Hospital of Richmond at VCURichmond, United StatesContact: Michelle OlsonTaking people
  • Seattle Children'sSeattle, United StatesContact: Joan RobertsTaking people
  • Washington University in St. LouisSt Louis, United StatesContact: Ashley TurnerTaking people
  • Nemours Children's HealthWilmington, United StatesContact: Yosef LevenbrownTaking people

About the trial

What the trial wants to find out

Pediatric cardiac arrest is a life-threatening problem affecting >15,000 hospitalized children each year. Less than half of these children survive to hospital discharge, and neurologic morbidity is common among survivors. The objective of this study is to evaluate the effectiveness of the OPTI-VENT bundle to improve survival to discharge with favorable neurological outcome (Pediatric Cerebral Performance Category Score 1-2 or no change from baseline) among children receiving at least 1 minute of CPR.

The 14 groups in the trial

  • ControlTreatment being tested

    Standard ICU resuscitation practices throughout study

    Treatment: None - control

  • OPTI-VENT BundleTreatment being tested

    Provider Education: During a brief (\<2 minute) bedside education, the educator will 1) review the CPR ventilation rate targets for age, and 2) ensure the provider has a cue card of current rate recommendations on his/her person. Compliance will be defined as performance of at least 30 trainings per unit per month. We will record provider discipline and time since last training as a surrogate of training spread. Educators will leverage these two-minute trainings to review the patient's current ventilator settings as an initial target during CPR to ensure adequate chest rise. Additionally, a focus on CPR ventilation rates will be integrated into resuscitation education or quality meetings for all disciplines. "Report cards" detailing unit-level performance will be generated by the study team for review during site monthly presentations. Point-of-Care Guidance: A metronome will be deployed to all cardiac arrests using a smart phone application.

  • Site 5Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 6Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 7Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 8Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 9Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 10Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 11Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 12Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 13Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 14Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 15Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

  • Site 16Treatment being tested

    Study enrollment will begin on the control arm. There will be a 2-month transition period as they onboard to the intervention. And the remainder of the study period will be on the OPTI-VENT Bundle intervention.

    Treatment: OPTI-VENT Bundle, Transition, and None - control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
OPTImal Ventilation to Improve Pediatric Cardiac Arrest Outcomes (OPTI-VENT)
Record updated
21 October 2026